<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522843</url>
  </required_header>
  <id_info>
    <org_study_id>GVHD_Def</org_study_id>
    <nct_id>NCT04522843</nct_id>
  </id_info>
  <brief_title>Analysis of Intestinal Defensin Expression in Acute GVHD</brief_title>
  <official_title>Analysis of Intestinal Defensin Expression in Patients With Acute Graft-versus-Host Disease (GVHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has the aim to analyze intestinal expression of endogenous antimicrobial peptides&#xD;
      in patients with acute GVHD. The expression will be compared to intestinal expression of&#xD;
      defensins in patients with colitis and patients without intestinal inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in&#xD;
      patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Acute GVHD is&#xD;
      characterized by complex deficiencies of the mucosal antimicrobial barrier and intestinal&#xD;
      dysbiosis, which contribute to disease pathogenesis. Defensins are endogenous epithelial&#xD;
      cell-derived antimicrobial peptides, which can protect epithelial barrier integrity, shape&#xD;
      the intestinal microbiota composition and contribute to host immunoregulation. Deregulated&#xD;
      expression of defensins has been reported in patients with colitis, including Chron's Disease&#xD;
      and ulcerative colitis.&#xD;
&#xD;
      In this study, the investigators aim to analyze the expression of defensins in the intestine&#xD;
      of patients with acute GVHD to study whether it is deregulated. The results will be valuable&#xD;
      to study the role of defensins during acute GVHD pathogenesis or as potential biomarkers for&#xD;
      disease activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Defensin Expression (mRNA)</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis of alpha-defensin and beta-defensin mRNA expression by realtime PCR (qRT-PCR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Defensin Expression (peptide)</measure>
    <time_frame>3 years</time_frame>
    <description>Analysis of alpha-defensin and beta-defensin levels by immunohistochemistry</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>GVHD,Acute</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Morbus Crohn</condition>
  <arm_group>
    <arm_group_label>Uninflamed intestine</arm_group_label>
    <description>Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colitis</arm_group_label>
    <description>Patients with active colitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute GVHD</arm_group_label>
    <description>Patients with acute gastrointestinal (GI) GVHD</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients who underwent diagnostic endoscopy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  diagnostic endoscopy was performed&#xD;
&#xD;
          -  diagnosis results available&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  ability to understand the nature of the study and the study related procedures and to&#xD;
             comply with them&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
&#xD;
          -  gastrointestinal cancer&#xD;
&#xD;
          -  lack of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zeiser, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center University of Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Center University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Wehkamp J, Fellermann K, Herrlinger KR, Baxmann S, Schmidt K, Schwind B, Duchrow M, Wohlschläger C, Feller AC, Stange EF. Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002 Jul;14(7):745-52.</citation>
    <PMID>12169983</PMID>
  </reference>
  <reference>
    <citation>Köhler N, Zeiser R. Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD. Front Immunol. 2019 Jan 17;9:3179. doi: 10.3389/fimmu.2018.03179. eCollection 2018. Review.</citation>
    <PMID>30705680</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Robert Zeiser</investigator_full_name>
    <investigator_title>Director of the Division of Tumor Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

